Johnson & Johnson (US) and Stryker (US) are Leading Players in the Sinus Dilation Devices Market
The global sinus dilation devices market is expected to reach USD 3.8 billion by 2027 from USD 2.8 billion in 2022, at a CAGR of 6.6% during the forecast period. The growth of this market is majorly driven by High prevalence of chronic sinusitis and Benefits of balloon dilation procedures over traditional endoscopic sinus surgeries. However, Dearth of skilled otolaryngologists, ENT surgeons, and endoscopists is one of the challenges for which may hinder the growth of this market.
The sinus dilation devices market is fragmented. The key players operating in this market are Acclarent, inc. (a subsidiary of Johnson & Johnson) (US), Olympus Corporation (Japan), Entellus Medical Inc. (A Subsidiary of stryker) (US), Medtronic Plc. (Ireland), Smith & Nephew plc (UK), Intersect ENT, Inc. (US), SinuSys Corporation (US), InnAccel Pvt. Ltd (India), MERIL LIFE SCIENCES PVT Ltd. (India), Optim LLC (US).
To know about the assumptions considered for the study download the pdf brochure
Johnson & Johnson (US)
Johnson & Johnson is one of the leading players in the sinus dilation devices market. In 2021 it is accounted for the largest share of 12–14% of the sinus dilation devices market in 2021. In 2021, the company invested USD 14.7 billion in R&D activities (15.7% of the total revenue). Its extensive R&D enables it to enhance its technology and service capabilities. A significant focus on R&D activities also helps the company provide innovative products as well as maintain and improve its competitive position in the sinus dilation devices market space. With its broad product portfolio, strong marketing efforts, and wide geographic presence, the company is expected to grow at a high rate in the sinus dilation devices market during the forecast period.
Stryker (US)
Stryker holds a prominent position in the sinus dilation device devices market due to its strong brand recognition and robust product portfolio. The company focuses on adopting organic and inorganic growth strategies to maintain and enhance its presence in the market. This is evident by the company’s recent developments in the past few years. The company also focuses extensively on research and development activities to strengthen its position in the market. In 2020, the company invested USD 0.98 billion in R&D activities to develop new products. With its broad product portfolio, strong marketing efforts, and wide geographic presence, the company is expected to grow at a high rate in the sinus dilation devices market during the forecast period.
Intersect ENT, Inc. (US)
Intersect ENT, Inc. (US) is a medical technology company that specializes in ENT treatment-related products. The company provides physicians with solutions to overcome clinical challenges and improve the quality of life of patients. Intersect ENT’s initial focus is on improving the treatment of chronic sinusitis. The company designs and manufactures a wide range of sinus implants to treat this condition. The company mainly focuses on the US market for its sales and distribution. In 2021, the company invested USD 27.9 million in research and development activities.
Related Reports:
Sinus Dilation Devices Market by Product (Balloon Dilation Devices, Endoscope (Rhinoscope, Sinoscope), Handheld), Procedure (Standalone, Hybrid), Patient Type (Adult, Pediatric) & Patient Care Setting (Hospitals & ASC, ENT Office) - Global Forecast to 2027
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
